 | |
 Lithium salicylate (top) and L-proline (bottom) | |
| Combination of | |
|---|---|
| Lithium salicylate | Lithium salt |
| L-Proline | Amino acid |
| Clinical data | |
| Trade names | AL-001, Lithium salicylate/L-proline cocrystal, LiProSal, LISPRO |
| Routes of administration | oral |
| Drug class | Mood stabilizer |
Lithium cocrystal (AL-001, Lithium salicylate/L-proline cocrystal, LiProSal, LISPRO) is a form of lithium that combines lithium salicylate and the amino acid L-proline. [1] [2] The ionic cocrystal (ICC) form combines the lithium salt with an organic anion. [3] [4] This formulation allows more of the compound to cross the blood brain barrier and into the central nervous system. [5] The lithium salicylate/L-proline cocrystal allows approximately 20% lower blood serum levels versus lithium carbonate, and thus fewer attendant side effects. [6] [7] The compound is in phase 2 clinical trials for Alzheimer's disease, bipolar disorder, major depressive disorder and PTSD. [8] Lithium cocrystal was created in 2004 at the University of South Florida. [6] It is under development by Alzamend Neuro with the designation AL-001. [8] [9] [10]
